/

ALDX

Aldeyra Therapeutics, Inc.Closed

0.8998−0.01 −0.66%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.8900 −1.09%

Open

0.8900

Prev close

0.9058

Day range

0.86520.9100

52-week range

0.86205.93

Volume

1.45M1.24×

Mkt cap

54.28M

P/E ttm

—

Fwd P/E

-3.27

EPS ttm

-0.3800

Div yield

0.00%

Earnings

—

From 52w high

−84.83%

Price Chart

Yahoo Finance · delayed

ALDXOct 12, 2026O 0.9200H 0.9400L 0.8820C 0.9060−0.0100 (−1.09%)Vol 1.34M

SMA 501.3837
SMA 2002.5507

1Y change −83.19% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ALDX Aldeyra Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.95%
1 month: −32.39%
3 months: −53.06%
6 months: −49.67%
Year to date: −82.51%
1 year: −83.19%

Valuation & ownership

Market cap: 54.28M
Enterprise value: 9.34M
P/E (ttm): —
Forward P/E: -3.27
PEG ratio: —
Price / book: 1.43
Price / sales (ttm): —
EV / EBITDA: -0.39
EPS (ttm): -0.3800
EPS (forward): -0.2750
Beta (5y monthly): 1.20
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 60.33M
Float: 48.95M
Short % of float: 5.94%
Short ratio (days): 3.70
Held by insiders: 3.60%
Held by institutions: 61.52%
Avg volume (3m): 1.17M
50-day average: 1.38
200-day average: 2.55
52-week change: −83.19%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 29.5
vs 50-day SMA: −34.52%
vs 200-day SMA: −64.48%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 11.37%
Realised vol (20d, ann.): 115.1%
From 52-week high: −84.72%
From 52-week low: +5.10%

ANR

Analyst Consensus

5 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

6.60

+633.50% implied

Low 2.00Median 5.00High 13.00

Recommendation trend

Now5 / 1 / 0
1m ago / 1 /

DES

About Aldeyra Therapeutics, Inc.

Yahoo Finance profile

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 6
Headquarters: Lexington, MA, United States
Website: aldeyra.com
Officers: Dr. Todd C. Brady M.D., Ph.D. CEO, President & Director
Mr. Michael Alfieri Head of Finance and Principal Financial & Accounting Officer
David Burke Head of Investor Relations

SEAS

Seasonality · ALDX

2014–2026 · monthly returns

Strongest month Sep +16.98%Weakest month Oct −9.19%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	3.5	1.9	-69.0	-10.1	15.1	21.7	-27.7	-3.9	-16.9	-26.8			−82.6%
2025	5.0	-2.5	12.5	-53.9	-18.9	78.1	30.3	17.0	-10.6	-2.9	8.1	-5.5	+3.8%
2024	-10.8	15.7	-9.7	20.5	-2.0	-14.2	19.0	46.1	-6.3	-2.4	-6.8	1.8	+42.2%
2023	-15.2	14.6	46.9	-4.0	-0.4	-11.6	-3.3	-8.1	-10.5	-74.4	62.0	26.7	−49.6%
2022	-8.2	10.1	10.0	-30.9	0.7	29.1	26.3	39.7	-24.1	2.2	2.6	24.3	+74.0%
2021	63.3	9.5	-3.1	5.8	-0.4	-9.5	-21.4	6.6	-7.5	3.6	-15.7	-47.8	−41.7%
2020	-8.1	-28.8	-35.0	27.5	56.2	-15.2	54.2	1.6	13.5	-9.9	5.2	-2.4	+18.1%
2019	6.1	-8.3	11.8	-8.4	-15.7	-13.9	-8.7	-19.5	19.5	6.1	42.8	-27.2	−30.0%
2018	9.9	10.4	-9.1	4.7	7.0	-5.4	-12.6	21.6	63.3	-22.0	-16.7	-7.5	+22.1%
2017	1.9	-9.2	1.0	-13.0	16.1	-7.9	2.2	-12.6	73.5	-12.5	5.6	2.3	+27.1%
2016	-29.1	1.9	-14.5	50.4	-7.8	-2.1	8.1	-9.9	41.2	-32.9	-1.9	3.9	−21.1%
2015	67.6	-15.7	-0.2	-7.2	-21.1	4.2	14.6	-18.8	-19.3	18.0	5.8	-6.9	−6.1%
2014						7.5	-45.6	-3.1	71.1	16.6	4.6	0.0	+18.3%

INSD

Insider Activity · ALDX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 2, 2026	Brady Todd CChief Executive Officer	Purchase at price 1.67 per share.	250K	$418.45K
Mar 18, 2026	Douglas Richard HDirector	Purchase at price 1.83 per share.	70K	$128.10K
Mar 17, 2026	Alfieri Michael LChief Financial Officer	Purchase at price 1.42 per share.	5K	$7.10K
Aug 12, 2025	Alfieri Michael LChief Financial Officer	Purchase at price 5.30 per share.	2.5K	$13.25K
Aug 10, 2025	Machatha StephenOfficer	Sale at price 5.15 per share.	22.1K	$113.71K
Apr 2, 2025	Perceptive Advisors L L CBeneficial Owner of more than 10% of a Class of Security	Sale at price 1.42 per share.	3.40M	$4.83M

13F

Investors Holding ALDX

latest 13F filings of 29 followed managers

Investors holding ALDX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.9M	0.00%	882.00K	+2.2%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ALDX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ALDX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Aldeyra Therapeutics, Inc.

Seasonality · ALDX

Insider Activity · ALDX

Congress Trades · ALDX

Investors Holding ALDX

Investors Holding ALDX

Congress Trades · ALDX

Insider Activity · ALDX

Seasonality · ALDX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Aldeyra Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News